Moderna Begins First Human Trial of mRNA Ebola Vaccine as Second-Deadliest Outbreak Accelerates

The Outbreak Context

The outbreak was first reported on May 14, 2026 in Ituri Province, Democratic Republic of the Congo (DRC) . Both the DRC and Uganda declared outbreaks on May 15, 2026, and the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) on May 17, 2026 .

As of July 30, 2026, the WHO reported 3,605 confirmed cases and 1,587 deaths in the DRC, corresponding to a case fatality rate of approximately 44% . Uganda and neighboring countries have also reported cases . The outbreak has spread across multiple health zones and provinces, with the highest weekly number of cases and deaths recorded in late July 2026 .

Comparison to the 2014–2016 West Africa Epidemic

The 2014–2016 West Africa outbreak (caused by Zaire ebolavirus) was far larger — approximately 28,600 cases and 11,300 deaths. The current Bundibugyo outbreak is the second-largest Ebola outbreak on record, but remains substantially smaller than the West Africa epidemic. A critical complication: existing licensed Ebola vaccines and treatments target Zaire ebolavirus, not Bundibugyo, leaving this outbreak with no approved countermeasures .

CEPI Funding Commitment

The Coalition for Epidemic Preparedness Innovations (CEPI) has committed up to $50 million to support Moderna's mRNA-1469 program . This funding covers preclinical testing, the Phase 1 trial, manufacturing, and potential progression to later-stage trials if early data are positive . This is part of a larger CEPI allocation of approximately $60 million spread across three vaccine developers: Moderna, the University of Oxford, and IAVI .

Access and Pricing Commitments

If the vaccine is approved, Moderna has committed to make at least 500,000 doses available at access pricing for low- and middle-income countries, and to supply doses to the DRC and other affected nations during the outbreak response .

Comparison with Oxford's ChAdOx1 Bundibugyo Vaccine

Oxford's ChAdOx1 BDBV vaccine trial (BD-Ebov) launched on July 13, 2026 — roughly three weeks before Moderna's trial — making it the world's first human trial of a Bundibugyo-specific vaccine . The first volunteer was dosed on July 24, 2026 . The Oxford trial is being conducted at the Oxford Vaccine Group in the UK and is enrolling 50 healthy adults aged 18–55 . Oxford's vaccine uses the same ChAdOx1 viral-vector platform as the Oxford-AstraZeneca COVID-19 vaccine .

Both are early-stage safety and immunogenicity studies. Researchers aim to test Oxford's vaccine in outbreak settings in Uganda later in 2026, and Moderna's candidate could follow a similar accelerated pathway if early data are positive .